Products & Programs PharmacyAnthem Blue Cross and Blue Shield | CommercialSeptember 1, 2023

Notice of material change/amendment to contract

Specialty pharmacy updates – September 2023

Specialty pharmacy updates for Anthem Blue Cross and Blue Shield (Anthem) are listed below.

Prior authorization clinical review of non-oncology use of specialty pharmacy drugs is managed by the Anthem's Medical Specialty Drug Review team. Review of specialty pharmacy drugs for oncology use is managed by Carelon Medical Benefits Management, Inc.*, a separate company.  

Important to note: Currently, your patients may be receiving these medications without prior authorization. As of the effective date below, you may be required to request prior authorization review for your patients’ continued use of these medications.

Including the National Drug Code (NDC) code on your claim may help expedite claim processing of drugs billed with a not otherwise classified (NOC) code. 

Prior authorization updates

Effective for dates of service on and after December 1, 2023, the following specialty pharmacy codes from current or new Clinical Criteria documents will be included in our prior authorization review process. 

Access our Clinical Criteria to view the complete information for these site of prior authorization updates.

Clinical Criteria

Drug

HCPCS or CPT® code(s)

CC-0241

Elfabrio (pegunigalsidase alfa-iwxj)

J3490, J3590

CC-0242*

Epkinly (epcoritamab-bysp)

C9399, J3490, J3590, J9999

CC-0243

Vyjuvek (beremagene geperpavec)

J3490, J3590

CC-0062

Yuflyma (adalimumab-aaty)

J3490, J3590

* Oncology use is managed by Carelon Medical Benefits Management.

Note: Prior authorization requests for certain medications may require additional documentation to determine medical necessity.

Quantity limit updates

Effective for dates of service on and after December 1, 2023, the following specialty pharmacy codes from current or new clinical criteria documents will be included in our quantity limit review process.

Access our Clinical Criteria to view the complete information for these quantity limit updates.

Clinical Criteria

Drug

HCPCS or CPT® Code(s)

CC-0241

Elfabrio (pegunigalsidase alfa-iwxj)

J3490, J3590

CC-0228

Leqembi (lecanemab)

J0174

CC-0243

Vyjuvek (beremagene geperpavec)

J3490, J3590

CC-0062

Yuflyma (adalimumab-aaty)

J3490, J3590

* Carelon Medical Benefits Management, Inc. is an independent company providing utilization management services on behalf of the health plan.

MULTI-BCBS-CM-034766-23-CPN34723

ATTACHMENTS: Epkinly 7.11.23 CC-0242 (pdf - 0.12mb), Vyjuvek 7.11.23 CC-0243 (pdf - 0.17mb), Elfabrio 7.11.23 CC-0241 (pdf - 0.19mb), Leqembi 7.21.23 CC-0228 (pdf - 0.42mb), Tumor Necrosis Factor Antagonists_Yuflyma 7.24.23 CC-0062 (pdf - 0.69mb)

PUBLICATIONS: September 2023 Provider Newsletter